• 제목/요약/키워드: Collecting Duct Carcinoma

검색결과 3건 처리시간 0.031초

신장 집합관 암종의 세침흡인 세포학적 소견 - 1예 보고 - (Fine Needle Aspiration Cytology of Collecting Duct Carcinoma of the Kidney - A Case Report -)

  • 이상엽;이광길
    • 대한세포병리학회지
    • /
    • 제5권2호
    • /
    • pp.160-166
    • /
    • 1994
  • Collecting duct carcinoma of the kidney is an unusual variety of renal carcinoma considered to arise from the epithelium of the collecting ducts. We recently experienced a case of fine needle aspiration cytology of collecting duct carcinoma of the kidney in a 17 year-old girl. The smear revealed many cellular clusters of ordinary papillary pattern, characterized by clumping of cells with nuclear overlapping, in a slightly necrotic background. The tumor cells had abundant delicate granular cytoplasm with some having vacuolation. The nuclei were only slightly pleomorphic with somewhat coarse chromatin and one or more small nucleoli Some nuclei showed irregular nuclear membrane and nuclear groove. A few polymorphs were also present.

  • PDF

동측 신장에서 발생한 동시성 집합관세포암종과 요로상피세포암: 2예 보고 (Urothelial Carcinoma of the Renal Pelvis with Synchronous Ipsilateral Collecting Duct Carcinoma: Two Case Reports)

  • 배상빈;윤성국;나서희
    • 대한영상의학회지
    • /
    • 제85권1호
    • /
    • pp.222-229
    • /
    • 2024
  • 신장의 동시성 악성종양은 드물게 발견되며, 신장 수술 후 진단된다. 신세포암과 요로상피세포암이 함께 동반되는 경우가 가장 많이 보고 되었다. 대부분의 경우 신세포암의 아형은 투명세포형 신세포암이지만, 동시성 집합관세포암종과 요로상피세포암이 동반되는 경우에 대한 보고는 매우 드물다. 동측 신장에서 발생한 동시성 집합관세포함종과 요로상피세포암의 2건의 증례를 보고한다.

Loss of Nuclear BAP1 Expression Is Associated with High WHO/ISUP Grade in Clear Cell Renal Cell Carcinoma

  • Wi, Young Chan;Moon, Ahrim;Jung, Min Jung;Kim, Yeseul;Bang, Seong Sik;Jang, Kiseok;Paik, Seung Sam;Shin, Su-Jin
    • 대한병리학회지
    • /
    • 제52권6호
    • /
    • pp.378-385
    • /
    • 2018
  • Background: BRCA1-associated protein 1 (BAP1) mutations are frequently reported in clear cell renal cell carcinoma (ccRCC); however, very few studies have evaluated the role of these mutations in other renal cell carcinoma (RCC) subtypes. Therefore, we analyzed BAP1 protein expression using immunohistochemistry in several RCC subtypes and assessed its relationship with clinicopathological characteristics of patients. Methods: BAP1 expression was immunohistochemically evaluated in tissue microarray blocks constructed from 371 samples of RCC collected from two medical institutions. BAP1 expression was evaluated based on the extent of nuclear staining in tumor cells, and no expression or expression in <10% of tumor cells was defined as negative. Results: Loss of BAP1 expression was observed in ccRCC (56/300, 18.7%), chromophobe RCC (6/26, 23.1%), and clear cell papillary RCC (1/4, 25%), while we failed to detect BAP1 expression loss in papillary RCC, acquired cystic disease-associated RCC, or collecting duct carcinoma. In ccRCC, loss of BAP1 expression was significantly associated with high World Health Organization (WHO)/International Society of Urological Pathology (ISUP) grade (p=.002); however, no significant correlation was observed between loss of BAP1 expression and survival in ccRCC. Loss of BAP1 expression showed no association with prognostic factors in chromophobe RCC. Conclusions: Loss of BAP1 nuclear expression was observed in both ccRCC and chromophobe RCC. In addition, BAP1 expression loss was associated with poor prognostic factors such as high WHO/ISUP grade in ccRCC.